Oncolytic viruses for the treatment of cancer and genetic disease has been an area of active study for decades. Testing strategies for monitoring efficacy and safety of such therapeutics includes biomarker, biodistribution, viral shedding and infectivity assays.
Assessing the risk level for individual programs can drive the use of these bioanalytical methods and help shape overall strategy. Logistics for sample collection and handling, as well as the use of the data for these tests, are critical for understanding preclinical and clinical oncolytic virus programs.
This webinar covers each of these topics, highlighting current expectations from regulatory agencies.
What will you learn?
To recognize the applications of oncolytic viruses for therapeutic use
To identify testing strategies to support safety and efficacy of oncolytic therapeutics
To understand common challenges and regulatory expectations for bioanalysis in support of these programs